Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000595379 | SCV000706046 | uncertain significance | not provided | 2017-02-08 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001210603 | SCV001382099 | uncertain significance | Congenital myasthenic syndrome 4A | 2022-04-08 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 40 of the CHRNE protein (p.Arg40Trp). This variant is present in population databases (rs754001856, gnomAD 0.003%). This missense change has been observed in individual(s) with congnital myasthenic gravis (Invitae). ClinVar contains an entry for this variant (Variation ID: 500208). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CHRNE protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002483618 | SCV002786872 | uncertain significance | Congenital myasthenic syndrome 4A; Congenital myasthenic syndrome 4C; Congenital myasthenic syndrome 4B | 2021-09-28 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000595379 | SCV003830613 | uncertain significance | not provided | 2019-08-28 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001835868 | SCV002087534 | uncertain significance | Congenital myasthenic syndrome | 2020-08-03 | no assertion criteria provided | clinical testing | |
Zotz- |
RCV001210603 | SCV004101042 | uncertain significance | Congenital myasthenic syndrome 4A | 2023-11-02 | no assertion criteria provided | clinical testing |